Paraneoplastic syndrom
Authors:
Š. Forejtová
Authors place of work:
Revmatologický ústav Praha
Published in the journal:
Čes. Revmatol., 27, 2019, No. 4, p. 186-202.
Category:
Review Article
Summary
Paraneoplastic syndromes represent various manifestations of the primarily formed tumor, which, however, can be occult at the time of the appearance of the paraneoplastic symptomatology. They are caused by a wide spectrum of distant effects of tumors, which are not related to the mechanical action of tumor masses or distant metastases. The pathogenesis of paraneoplastic manifestations is not yet quite clear, but these syndromes usually arise as a result of secretions of hormones, peptides and various cytokine cells of the tumor, or as an immune-mediated cross-reaction between malignant and normal tissues. A number of paraneoplastic manifestations precede their own manifestations of malignancy by several months or even years, their good knowledge can contribute to the timely diagnosis of the tumor and thus to the early initiation of treatment. The course of the symptomatology of paraneoplastic syndrome often replicates the actual course of the tumor, when paraneoplastic syndrome is resolved after cure of the malignancy, and the reappearance of its manifestations is a sign of recurrence of malignancy. In some cases, for example, in paraneoplastic syndromes with neurological manifestations, there may be irreversible changes due to cross-reactivity between the tumor and the nervous tissue. Haematological paraneoplastic syndromes are often otherwise clinically asymptomatic, and they are usually a manifestation of advanced malignancy.
Keywords:
paraneoplastic syndrome – cancer-associated myositis – paraneoplastic synovitis – paraneoplastic vasculitis – paraneoplastic bone disease
Zdroje
1. Oppenheim H. Über Hirn Symptome bei Carcinamatóse ohne nachweisbare Veränderungen in Gehirn. Charité-Annalen (Berlin) 1888; (13): 335–344.
2. Kankeleit H. Über primare nichteirige Polymyositis. Dtsch Arch Klin Med 1916; 120: 335–349.
3. Guichard A, Vignon G. La Polyradiculonéurite cancéreuse métastatique. J Med Lyon 1949; 30: 197–207.
4. Baijens LW, Manni JJ. Paraneoplatic syndromes in patients with primary malignancies of the head and neck: four cases and review of the literature. Eur Arch Otorhinolaryngol 2006; 263: 32–36.
5. Pines A, Kaplinsky N, Olchovsky D, et al. Rheumatoid arthritis-like syndrom: s presenting symptom of malignancy. Report of 3 cases and review of the literature. Eur J Inflamm 1984; 7: 51–55.
6. Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis 2014; 17: 640–645.
7. Morel J, Deschamps V, Toussirot E, et al. Charakteristics and survival of 26 patients with paraneoplatic arthritis. Ann Rheum Dis 2008; 67: 244–247.
8. von Bamberger E. Veränderungen der Röhrenknochen bei Bronchiaktasie. Wien Klin Wochenschr 1889; 2: 226–240.
9. Craig JW. Hypertrophic pulmonary osteoartropathy as the first symptom of pulmonary neoplasm. Br Med J 1937; 1: 750–752.
10. Azar L, Khasnis A. Paraneoplastic rheumatology syndromes. Curr Opin Rheumatol 2013; 25: 44–49.
11. Jayakar BA, Abison AG, Yao O. Treatment of hypertrophic osteoartropathy with zolendronic acid: case report and review of literature. Semin Arthritis Rheum 2011; 41: 291–296.
12. Emmerson BT. The management of gout. N Eng J Med 1996; 334: 445–451.
13. Dylewski J, Luterman L. Septic arthritis and Clostridium septicum: a clue to colon cancer. CMAJ 2010; 182: 1446–1447.
14. Garcia-Porrua C, Gonzales-Gay MA, Monterroso JT, et al. Septic arthritis due to Streptococcus bovis as presenting sign of „silent“ colon carcinoma. Rheumatology 2000; 39: 338–339.
15. Hashefi M. Rheumatologic manifestation of malignancy. Clin Geriatr Med 2017; 33: 73–86.
16. Vencovský J. Revmatické projevy nádorových onemocnění. In: Pavelka K, Vencovský J, Horák P, Šenolt L, Mann H, Štěpán J. Revmatologie, druhé vydání. Praha: Maxdorf 2018; 744–747.
17. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134: 1087–1092.
18. Sparsa A, Liozon E, Herrmann F, et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 2002; 138: 885–890.
19. Schoser B, Eymard B, Datt J, Mantegazza R. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol 2017; 264: 1854–1863.
20. Carpenter TO. Oncogenic osteomalacia: a complex dance of factores. N Eng J Med 2003; 348: 1705–1708.
21. Fain O, Hamidou M, Cacoub P, et al. Vaskulitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 2007; 57: 1473–1480.
22. Solans-Laque R, Bosch-Gil JA, Perez-Bccanerga C, et al. Paraneoplastic vaskulitis in patients with solid tumors: report of 15 cases. J Rheumatol 2008; 35: 294–304.
23. Park HJ, Ranganathan P. Neoplastic a paraneoplastic vaskulitis, vaskulopathy, and hyperkoagulability. Rheum Dis Clin North Am 2011; 37: 593–606.
24. Hasler P, Kistler P, Gerber H. Vaskulitides in hairy cell leukemia. Semin Arthritis Rheum 1995; 25: 134–142.
25. Han JH, Lee JB, Kim SJ, et al. Paraneoplastic erytromelalgia associated with breast carcinoma. Int J Dermatol 2012; 51: 878–880.
26. Skeik N, Rooke TW, Davis MD, et al. Severe case and literature review of primary erythromelalgia: novel SCN9A gene mutation. Vasc Med 2012; 17: 44–49.
27. Bermer C. Shloulder hand syndrome. A case of unusual etiology. Ann Phys Med 1967; 9: 168–171.
28. Medsger TA, Dixon JA, Garwood VF. Palmar fascitis a polyarthritis associated with ovarian carcinoma. Ann Intern Med 1982; 96: 424–431.
29. Lakhanpal S, Ginsburg WW, Michet CJ, et al. Eosinophlic fascitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 1988; 17: 221–231.
30. Lebeaux D, Francès C, Barete S, et al. Eosinophilic fascitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology (Oxford) 2012; 51: 557–561.
31. Narvaez J, Bianchi MM, Santo P, et al. Pancreatitis, panniculitis, and polyarthritis. Semin Arthritis Rheum 2010; 39: 417–423.
32. Radin DR, Colleti PM, Forrester DM, Tang WW. Pancreatic acinar cell carcinoma with subcutaneous and intraosseous fat necrosis. Radiology 1986; 158: 67–68.
33. Tannenbaum H, Anderson LG, Schur PH. Association of polyarthritis, subcutaneous nodules, and pancreatic disease. J Reumatol 1975; 2: 15–20.
34. Racanelli V, Prete M, Minoia C, et al. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 2008; 7: 352–358.
35. Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2015; 66: 551–553.
36. Evans KG, Heymann WR. Paraneoplastic subacute cutaneous lupus erythematosus: an under–recognized entity. Cutis 2013; 91: 25–29.
37. Cohen PR, Kurzrock R. Sweet’s syndrome revisited, a review of disease concepts. Int J Dermatol 2003; 42: 761–778.
38. Cossins, L, Okell RW, Cameron H, et al. Treatment of complex regional pain syndrome in adults: a systematic review of randomized controlled trials published from June 2000 to February 2012. Eur J Pain 2013; 17: 158–73.
39. Li H, Altman RD, Yao Q. RS3PE: Clinical and Research Development. Curr Rheumatol Rep 2015; 17(8): 49.
40. Toz B, Büyükbabani N, Inanc M. Multicentric reticulohistiocytosis: Rheumatology perspective. Best Pract Res Clin Rheumatol 2016; 30: 250–260.
41. El-Haddad B, Hammoud D, Shaver T, Shahouri S. Malignancy associated multicentric histiocytosis. Rhematol Int 2011; 31: 1235–1238.
42. Snow JL, Muller SA. Malignancy-associated multicentric reticulohistiocytosis: a clinical, histological and imunophenotypic study. Br J Deramtol 1995; 133: 71–76.
43. Dispenzieri A. Diagnosis and treatment of POEMS syndrome. In: Rajkumar SV, Kyle RA. Treatment of multiple myeloma and related disorders. New York, NY, USA: Cambridge University Press 2009; 182–195.
44. Dispenzieri A. POEMS syndrome. Blood Rev 2007; 21: 285–299.
45. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long–term outcome. Blood 2003; 101: 2496–2506.
46. Kuwabara S, Misawa S, Kanai K, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 2006; 66: 105–107.
47. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc 2010; 85: 838–854.
48. Spinazze S, Schrijvers D. Metabolic emergencies. Crit Rev Oncol Hematol 2006; 58: 79–89.
49. Raftopulous H. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer 2007; 15: 1341–1347.
50. Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. N Engl J Med 2005; 356: 2064–2072.
51. Wysolmerski JJ. Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab 2012; 97: 2947–2956.
52. Lumachi F, Brunello A, Roma A, Basso U. Medical treatment of malignancy-associated hyperkalcemia. Curr Med Chem 2008; 15: 415–421.
53. Stewart AF. Hypercalcemia associated with cancer. N Eng J Med 2005; 352: 373–379.
54. Nayar MK, Lombard MG, Furlong NJ, et al. Diagnosis a management of nonislet cell tumor hypoglycemia: case series and review of literature. Endocrinologist 2006; 16: 227–230.
55. Hoff AO, Vassilopoulou-Sellin R. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. Cancer 1998; 82: 1585–1592.
56. Nimalasena S, Freeman A, Harland S. Paraneoplastic Cushing's syndrom in prostate cancer: a difficult management problem. BJU Int 2008; 101: 424–427.
57. Nieman LK. Medical therapy of Cushing’s disease. Pituitary 2002; 5: 77–82.
58. Didelot A, Honnorat J. Update on paraneoplastic neurological syndromes. Curr Opin Oncol 2009; 21: 566–592.
59. Shams’ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 52 patients. Brain 2003; 126: 1409–1418.
60. Ali N, Abbasi AN, Karsan F, et al. A case of finger clubbing associated with nasopharyngel carcinoma in a young girl, and review of pathophysiology. J Pak Med Assoc 2009; 59: 253–254.
61. Garganese MC, De Sio L, Serra A, et al. Rhabdomyosarcoma associated hypertrophic osteoartropathy in a child: detection by bone scintigraphy. Clin Nucl Med 2009; 34: 155–157.
62. Mekhail TM, Markman M. Acanthosis nigricans with endometrial carcinoma: case report and review of the literature. Gynecol Oncol 2002; 84: 332–334.
63. Anderson SH, Hudson-Peacock M, Muller AF. Malignant acanthosis nigricans: potential role of chemotherapy. Br J Dermatol 1999; 141: 714–716.
64. Thiers BH, Sahn RE, Callen JP. Cutaneous manifestation of internal malignancy. CA Cancer J Clin 2009; 59: 73–98.
65. Jameson JL, Johnson BE. Paraneoplastic syndromes: endokrinologic/hematologic. In: Fauci AS, Braunwald E, Kasper DL, Huaser SL, Longo DL, Jameson JL, Loscalzo J, etc. Harrison’s Principles of Internal Medicine. 17th ed. New York, NY: McGraw Hill Medical 2008; 617–622.
66. Kessler CM. The link between cancer and venous tromboembolism: a review. Am J Clin Oncol 2009; 32: S3–S7.
67. Ganger JM, Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retospective, single – institution study. Cancer 2009; 115: 3919–3923.
68. Sawada K, Hirokawa M,Fujishima N. Diagnosis and managment of acquired pure red cell aplasia. Hematol Oncol Clin North Am 2009; 23: 249–259.
69. Buss DH, Cashell AW, O’Connor ML, Richards F, Case LD. Occurence, etiology, and clinical signifikance of extreme thrombocytosis: a study of 280 cases. Am J Med 1994; 96: 247–253.
70. Imboden JB. Rheumatic manifestation of malignany. In: Imboden JB, Hellmann DB, Stone JH. Current Diagnosis & Treatment: Rheumatology, 3rd edition. The McGraww-Hill Companies 2013; 419–422.
Štítky
Dermatology & STDs Paediatric rheumatology RheumatologyČlánok vyšiel v časopise
Czech Rheumatology
2019 Číslo 4
Najčítanejšie v tomto čísle
- Paraneoplastic syndrom
- Recommendations of the Czech Society for Rheumatology for the treatment of gout
- Impact of inflammatory granulomas in rheumatic diseases
- The importance of achieving remission in patients with rheumatoid arthritis